WA-SORACOM
7.6.2022 11:02:13 CEST | Business Wire | Press release
Soracom , Inc., a global provider of advanced IoT connectivity, today announced that SPRESENSE™ from Sony Semiconductor Solutions Corporation (hereafter “SSS”) has joined the Soracom Partner Space ecosystem and SSS identified Soracom as a recommended provider of connectivity for its SPRESENSE microcontrollers.
SSS’s SPRESENSE 6-core microcontroller board is ideal for professional IoT use cases, with a streamlined form factor, ultra-low power consumption, multiple sensor inputs, internal GPS, and edge AI support. The unique combination of solid computing performance and advanced power efficiency makes SPRESENSE suitable for edge computing. SPRESENSE is featured in applications where there is a need for sensor analysis, machine learning, image processing and data filtering in which other microcontroller-based alternatives fall short.
SSS’s SPRESENSE LTE extension board offers an on-board antenna for global LTE Cat-M1 connectivity. Combined with Soracom’s global IoT connectivity, SSS’s SPRESENSE LTE extension board makes it easy to connect almost anywhere in the world, control connections through the Soracom console and API, and access a wide range of services supporting secure private networking, data and protocol management, and integration with leading cloud platforms.
"Collaboration with Soracom enables global connectivity to our IoT SPRESENSE solution, providing an out-of-the-box experience that ensures our customers can be dedicated to driving innovative IoT solutions, especially for Edge AI applications," said Kenichi Nakano, General Manager, Sony Semiconductor Solutions Corporation.
Supporting more than 4 million connections with global IoT coverage in more than 160 countries, Soracom offers a portfolio of powerful connectivity solutions that help IoT deployments connect securely and easily to leading hyperscaler platforms, reduce data and power requirements, and manage total cost of ownership at scale.
The Soracom Partner Space enables partners to access live opportunities and technical collaborations to provide services to IoT innovators around the world. In turn, customers are able to find trusted partners who will help them bring solutions to market and scale more quickly, create differentiators, and simplify the IoT journey. Soracom Partner Space partners have supported many of the projects behind Soracom’s expansion.
Soracom now offers the SPRESENSE LTE-M IoT Connectivity Kit in its online store. The package also includes the official LTE Extension board for SPRESENSE, a Soracom IoT SIM card, and access to Soracom connectivity and platform services.
“Soracom is committed to partnering with leaders in hardware, software, and services to offer customers a robust global ecosystem that accelerates speed to market and success at scale,” said Kenta Yasukawa, co-founder and CTO, Soracom. “Sony’s SPRESENSE offers IoT innovators an exceptional platform for creation of new connected experiences that take full advantage of edge and the cloud.”
For more information on the SPRESENSE LTE-M IoT Connectivity Kit or to purchase, visit the Soracom store or the SPRESENSE webpage .
SPRESENSE™ is a trademark of Sony Group Corporation.
About SPRESENSE™
SPRESENSE is a low-power board computer for the IoT that is equipped with a GPS receiver and supports High-Resolution Audio codecs. The board allows for IoT versatility and can be developed for a vast range of uses, such as a drone utilizing the GPS and high-performance processor, a smart speaker utilizing High-Resolution Audio recording and playback as well as the built-in full-digital amplifier, or a low-power time-lapse camera utilizing the camera interface. SPRESENSE will make the IoT smarter and more efficient.
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom